Free tool
FAERS Monitor: Zevalin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125019 or its brand name (Zevalin, Ibritumomab Tiuxetan). Reports on generic versions are filed under their own applications.
Reports
1,523
Serious
1,418
93% of reports
Hospitalization
611
Death reported
551
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- thrombocytopenia174
- sepsis172
- neutropenia141
- meningitis tuberculous128
- myelodysplastic syndrome98
- febrile neutropenia94
- off label use93
- progressive multifocal leukoencephalopathy90
- disease progression85
- anaemia84
- platelet count decreased84
- white blood cell count decreased83
- pancytopenia78
- pneumonia73
- mucosal inflammation72
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 146 |
| 2005 | 56 |
| 2006 | 85 |
| 2007 | 69 |
| 2008 | 78 |
| 2009 | 164 |
| 2010 | 101 |
| 2011 | 75 |
| 2012 | 63 |
| 2013 | 47 |
| 2014 | 35 |
| 2015 | 76 |
| 2016 | 46 |
| 2017 | 64 |
| 2018 | 96 |
| 2019 | 49 |
| 2020 | 64 |
| 2021 | 127 |
| 2022 | 21 |
| 2023 | 30 |
| 2024 | 14 |
| 2025 | 15 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,636 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| meningitis tuberculousSignal | 128 | 4105.2 | 3392.2 | 401,804 |
| progressive multifocal leukoencephalopathySignal | 90 | 152.4 | 124.6 | 13,242 |
| myelodysplastic syndromeSignal | 98 | 94.2 | 77.7 | 8,890 |
| mucosal inflammationSignal | 72 | 38.1 | 30.4 | 2,559 |
| thrombocytopeniaSignal | 174 | 21.5 | 18.7 | 3,397 |
| sepsisSignal | 172 | 21.3 | 18.5 | 3,325 |
| febrile neutropeniaSignal | 94 | 19.6 | 16.1 | 1,643 |
| pancytopeniaSignal | 78 | 19.3 | 15.5 | 1,337 |
| neutropeniaSignal | 141 | 14.3 | 12.2 | 1,745 |
| platelet count decreasedSignal | 84 | 10.9 | 8.8 | 748 |
| white blood cell count decreasedSignal | 83 | 10.6 | 8.6 | 714 |
| disease progressionSignal | 85 | 9.9 | 8.1 | 677 |
| anaemiaSignal | 84 | 6.1 | 4.9 | 355 |
| pneumoniaSignal | 73 | 3.1 | 2.5 | 104 |
| off label use | 93 | 1.5 | 1.2 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.